On Tuesday, Shares of Lexmark International Inc (NYSE:LXK), lost - 20.22% to $37.75.
Lexmark International declared financial results for the second quarter of 2015.
“Lexmark delivered strong growth in Higher Value Solutions revenue, which is comprised of Enterprise Software and Managed Print Services,” said Paul Rooke, Lexmark chairman and chief executive officer. “Despite the ongoing headwinds from the strong U.S. dollar and near-term laser supplies channel optimization particularly in EMEA, overall Lexmark delivered a good quarter.
Lexmark International, Inc., together with its auxiliaries, operates as a developer, manufacturer, and supplier of printing, imaging, device administration, managed print services (MPS), document workflow, and business process and content administration solutions worldwide. It operates through two segments, Imaging Solutions and Services (ISS), and Perceptive Software.
Shares of Depomed Inc (NASDAQ:DEPO), inclined 1.68% to $33.28, during its last trading session.
Depomed, confirmed that it has received a purported revised, highly conditional, unsolicited; and non-binding proposal from Horizon Pharma plc (HZNP) (“Horizon”) to acquire all of the outstanding shares of Depomed in an all-stock transaction presently valued at $33.00 per share.
Consistent with its fiduciary duties, Depomed’s Board of Directors, in consultation with its independent financial and legal advisors, will carefully review and evaluate the Revised Proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders. Depomed shareholders are advised to take no action at this time pending the review of the Revised Proposal by the Company’s Board of Directors.
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
Finally, Enerplus Corp (USA) (NYSE:ERF), ended its last trade with 2.75% gain, and closed at $7.47.
Enerplus Corporation, declared that a cash dividend in the amount of CDN$0.05 per share will be payable on August 14, 2015 to all shareholders of record at the close of business on July 30, 2015. The ex-dividend date for this payment is July 28, 2015.
The CDN$0.05 per share dividend is equivalent to about US$0.04 per share if converted using the current Canadian/US dollar exchange rate of 0.7693. The U.S. dollar equivalent dividend will be based upon the actual Canadian/US exchange rate applied on the payment date and will be net of any Canadian withholding taxes that may be applicable. Dividends paid by Enerplus are considered an “eligible dividend” for Canadian tax purposes. For U.S. income tax purposes, Enerplus’ dividend.
Enerplus Corporation, together with auxiliaries, engages in the exploration and development of crude oil and natural gas in the United States and Canada. The company primarily has interests in about 162,000 net acres of lands comprising about 77,000 net acres targeting the Stacked Mannville zones and 85,000 net acres targeting the Duvernay formation in the Deep Basin region, Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
